Clinical trial NCT04828304: PLASOMA Ultimate Safety & Efficacy Study
Official title: PLASOMA Ultimate Safety & Efficacy Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetic Foot Ulcer
Venous Leg Ulcer
Pressure Ulcer
Burn Wound
Skin Graft
Infected Surgical Wound
Skin Flap
Lead sponsor: Plasmacure
Sponsor class: INDUSTRY
Collaborators: name: Diabetes Fonds
name: Pathology and Medical Microbiology
First posted: 2021-04-02
Enrollment: 101
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the PULSE study are the followingL

A.To perform post market clinical follow up (PMCF) on safety and efficacy:

1. Safety: To confirm transient short-terms side effects and verify long-term/outstanding risks.
2. Efficacy: To confirm the performance of PLASOMA, i.e. the beneficial effect on bacterial load. B. Determine the effect of PLASOMA on wound surface area.

A secondary purpose is to examine the beneficial effects of PLASOMA on wound healing and to perform a health technology assessment (HTA).

This clinical study will be an open label two-armed randomized controlled trial (RCT), performed at at least three sites (multi-center) in the Netherlands.

The two arms are:

1. Control group: Standard wound care for 12 weeks or until healing, whichever occurs first;
2. Treatment group: Standard wound care + PLASOMA treatment for 12 weeks or until healing, whichever occurs first.

The frequency of PLASOMA treatment will be determined by the treating (para)medical professional based on the number of visits they would schedule for the standard wound care at the study site.

For all study subjects, the treatment frequency will be at least once per week (in order to have enough treatments for safety evaluation) and should not exceed once per day.

Follow up (FU) will be performed at three timepoints for both arms:

* FU1: 2 weeks after end treatment period
* FU2: 12 weeks after end treatment period
* FU3: 12 months after start treatment.


Eligibility criteria: Inclusion criteria:

INCL1: have a slow-healing or non-healing ulcer consisting of, but not limited to:

* diabetic ulcers (Wagner-Meggitt classification system/ University of Texas classification system: grades 1-3)
* venous ulcers
* pressure ulcers (international NPUAP/EPUAP classification system: categories/stages II-IV)
* burn wounds (second and third degree)
* skin grafts and flaps
* infected post-surgical ulcers. Standard wound care has not resulted in sufficient healing after at least two weeks (including first line care) (Ref 25, Ref 26).

Note: There is no upper limit for the duration that the wound exists. In case a subject has multiple wounds that meet the in- and exclusion criteria, the wound with the longest duration will be chosen for the study.

INCL2: have a wound with a minimum wound surface area of 0.5 cm2 and a maximum diameter of 4.5 cm (\~16 cm2 wound surface area for circular wounds).

INCL3: have a minimum age of 18 years old.

INCL4: for home care treatments only: have a grounded wall socket available for connection of PLASOMA.

Exclusion criteria:

EXCL1: the subject has one or more of the following contraindications for PLASOMA:

* the wound is very exudative, i.e. wounds in which moisture is visible again within a few minutes after patting dry.
* any implanted active electronic device, such as a pacemaker, is present.
* an electronic medical device is attached to the body, including electronic life support equipment, hearing aids, glucose sensors and insulin pumps. If the sole purpose of the medical device is monitoring, the subject is not excluded, but it should be noted that use of PLASOMA together with such devices has not been tested and may lead to erroneous operation of the attached device during PLASOMA treatment.
* Note: no exclusion if electronic medical device will be detached during PLASOMA treatment.
* a metal implant (including a stent) is present in the treatment area, i.e. the area between pad and electrode.
* a conductive connection from outside to inside the body at or near the heart is present, e.g. a catheter with electrolyte fluid.
* the subject has epilepsy
* the subject is pregnant
* the to-be-treated wound is located on the torso above the navel

EXCL2: the subject has any known malignant wound degeneration.

EXCL3: the subject receives treatment with immunosuppressive agents or oral corticosteroids; no exclusion if subject has received a stable dose for at least 2 months and the oral corticosteroid dose does not exceed 7.5 mg/day prednisone or equivalent.

EXCL4: the subject is receiving or likely to receive advanced wound therapies - such as negative pressure therapy, hyperbaric oxygen therapy, biologicals (e.g. skin substitutes, growth factors), electrophysical therapy - until FU1 for the to be-treated wound. Advanced wound dressings are not excluded.

EXCL5: the subject participates in another study which is likely to compromise the outcome of the PULSE study or the feasibility of the subject fulfilling the PULSE study.

EXCL6: the subject is unable to provide consent.

Primary outcomes:
measure: Safety PLASOMA - device related SAEs
timeFrame: 12 months
measure: Efficacy PLASOMA - bacterial load reduction - Staphylococcus aureus
timeFrame: once at week 1 (wound swab directly before and after first PLASOMA treatment)
measure: Efficacy PLASOMA - wound surface area reduction
timeFrame: 12 weeks
Secondary outcomes:
measure: Safety PLASOMA - all AEs
timeFrame: 12 months
measure: Safety PLASOMA - wound appearance
timeFrame: 24 weeks
measure: Efficacy PLASOMA - Bacterial load reduction
timeFrame: once at week 1 (wound swab directly before and after first PLASOMA treatment)
measure: Efficacy PLASOMA- wound healing
timeFrame: 12 weeks
measure: Efficacy PLASOMA - Quality of Life
timeFrame: 14 weeks
measure: Efficacy PLASOMA - Quality of Life
timeFrame: 14 weeks
measure: Efficacy PLASOMA - Ulcer recurrence
timeFrame: 12 months
measure: Efficacy PLASOMA - wound infection
timeFrame: 12 weeks
measure: Efficacy PLASOMA - wound pain
timeFrame: 12 weeks
measure: Health Technology Assessment PLASOMA
timeFrame: 12 weeks
measure: Patient acceptability
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Gouda
country: Netherlands
facility: Groene Hart Ziekenhuis
city: Leiderdorp
country: Netherlands
facility: Alrijne Ziekenhuis
city: Nieuwegein
country: Netherlands
facility: Sint Antonius Ziekenhuis
city: Nijmegen
country: Netherlands
facility: radboud Universitair Medisch Centrum
city: Oosterhout
country: Netherlands
facility: Expertisecentrum Wondzorg (EcW)
city: Veldhoven
country: Netherlands
facility: Maxima Medisch Centrum (MMC)
Study officials:
affiliation: Plasmacure
name: Koen Lim
role: STUDY_DIRECTOR
References: